The objective of the proposed research is to synthesize actinomycin analogues suitable for conjugation to tumor-specific proteins. Such drug-protein conjugates should possess antitumor efficacy superior to that of actinomycin alone. Malignant cells would be subjected to far higher drug concentrations than those reaching normal cells, thus minimizing side effects. Targeting studies of this kind with other antitumor agents such as daunomycin and adriamycin have been reported. In order to succeed with this approach the following aspects must be considered: (a) Selection of a suitable drug: actinomycin is appropriate because of its stability and high potency. However, there is no group on the molecule suitable for covalent linkage to a protein. The principal objective of the proposed research will be to produce modified actinomycins which possess a linking group and retain antitumor potency. (b) Selection of the carrier protein: ideally this should consist of an antibody specific towards a tumor-associated antigen or a mixture of such antibodies. (c) Selection of a spacer group: such a group, interposed between drug and carrier, will be degraded by lysosomal enzymes after the conjugate enters the tumor cell, with release of the drug. Short peptides have proven valuable in this role. (d) Methodology of conjugation: this is a critical factor which must preserve both drug activity and antibody activity. This is a collaborative project. The principal investigator will synthesize actinomycins modified at various sites in the molecule and couple them to spacer peptides. Those modifications which retain antitumor activity comparable with that of actinomycin D will then be conjugated with antitumor antibodies by Dr. Meir Wilchek at the Weizmann Institute of science, Rehovoth, Israel. This collaborator, who has experience with daunomycin and adriamycin-antibody conjugates, will test the efficacy of the actinomycin-antibody conjugates in the related animal tumor systems. A number of possibilities will be produced and compared in order to identify the most efficacious analogue for targeting studies. It is hoped that such investigations will be extended to conjugates with human tumor antibodies and that the possibility of clinical trials will be realized.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA011627-18A1
Application #
3163500
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
1979-03-01
Project End
1987-11-30
Budget Start
1984-12-01
Budget End
1985-11-30
Support Year
18
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Washington Hospital Center
Department
Type
DUNS #
City
Washington
State
DC
Country
United States
Zip Code
20010
Nishino, Mizuki; Dahlberg, Suzanne E; Fulton, Linnea E et al. (2016) Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Acad Radiol 23:329-36
Nishino, Mizuki; Cardarella, Stephanie; Dahlberg, Suzanne E et al. (2015) Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol 84:998-1004
Nishino, M; Jackman, D M; DiPiro, P J et al. (2014) Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy. Clin Radiol 69:841-8
Nishino, Mizuki; Itoh, Harumi; Hatabu, Hiroto (2014) A practical approach to high-resolution CT of diffuse lung disease. Eur J Radiol 83:6-19
Nishino, Mizuki; Dahlberg, Suzanne E; Cardarella, Stephanie et al. (2013) Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer 119:3761-8
Nishino, Mizuki; Cardarella, Stephanie; Jackman, David M et al. (2013) RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol 201:W64-71
Nishino, Mizuki; Dahlberg, Suzanne E; Cardarella, Stephanie et al. (2013) Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol 8:1059-68
Nishino, Mizuki; Cardarella, Stephanie; Dahlberg, Suzanne E et al. (2013) Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 79:283-8
Nishino, Mizuki; Jagannathan, Jyothi P; Krajewski, Katherine M et al. (2012) Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198:737-45
Shinagare, Atul B; Okajima, Yuka; Oxnard, Geoffrey R et al. (2012) Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism. Lung Cancer 78:161-6

Showing the most recent 10 out of 22 publications